Sunshine on conflicts

Article metrics

US drug companies are preparing for new draconian provisions for reporting on financial relationships with academia. Will efforts to increase transparency prove burdensome to researchers and the industry? Virginia Hughes investigates.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Rockey, S.J. & Collins, F.S. J. Am. Med. Assoc. published online, doi: 10.1001/jama.2010.774 (24 May 2010).

  2. 2

    Levinson, D. CDC's ethics program for special government employees on federal advisory committees (CDC, Atlanta, Georgia, December, 2009). http://oig.hhs.gov/oei/reports/oei-04-07-00260.pdf

  3. 3

    Campbell, E.G. et al. J. Am. Med. Assoc. 298, 1779–1786 (2007).

  4. 4

    Contopoulos-Ioannidis, D.G. et al. Am. J. Med. 114, 477–484 (2003).

  5. 5

    Wazana, A. J. Am. Med. Assoc. 283, 373–380 (2000).

  6. 6

    Choudhry, N.K. et al. J. Am. Med. Assoc. 287, 612–617 (2002).

  7. 7

    Bekelman, J.E. et al. J. Am. Med. Assoc. 289, 454–465 (2003).

  8. 8

    Turner, E.H. et al. N. Engl. J. Med. 358, 252–260 (2008).

  9. 9

    Okike, K. et al. N. Engl. J. Med. 361, 1466–1474 (2009).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading